Results from studies on PARP inhibitors show that BRCA status and responsiveness to platinum analogues are much less binding that it was thought to achieve some improvements. But more clinical trials are needed to decide if PARP inhibitors should be used as part of first-line therapy or reserved for a later line [more]
PARP inhibitors are the first class of drugs to exploit a new concept in oncology – synthetic lethality. Alexandra Leary explains the rationale, reviews the trial evidence and clinical experience, and looks to their future [more]
The story of step-by-step progress, with occasional leaps forward and frequent setbacks, is not one the media enjoys telling. But it does need to be told if patients and society are to learn to live [more]